Description
The VA Greater Los Angeles Healthcare System’s Nuclear Medicine Service intends to procure two radiopharmaceutical products—Pluvicto and Lutathera—for treatment of advanced prostate cancer and neuroendocrine tumors. The Department of Veterans Affairs issued a Notice of Intent to award a sole‑source delivery order to Novartis Pharmaceuticals Corporation, but will consider qualified manufacturers or licensed distributors who submit a capability statement by the specified deadline. No price information is disclosed; respondents must be FDA‑certified and may cite existing GSA Federal Supply Schedule contracts if applicable.
• Products: Pluvicto (NDC 00078‑1217‑61) – 116 units; Lutathera (NDC 69488‑0003‑01) – 13 units.
• Intended use: Therapeutic radiopharmaceuticals for oncology patients at the VA Greater Los Angeles Nuclear Medicine Service.
• Eligibility: Must be a manufacturer or fully licensed distributor, FDA‑certified; can reference existing GSA FSS contracts.
• Submission: Capability statement (incl. SAM UEI, business size/type) in Word or PDF to Hestia Sim by 1 Nov 2026 10:00 AM PT.
• If no response, the VA will award the delivery order directly to Novartis without further notice.
Attached files
Contact
Hestia Sim(Contracting Officer)